Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus HICON.
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol sulfate is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
2 inhalations (each inhalation delivers 90 mcg albuterol sulfate and 18 mcg ipratropium bromide) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Albuterol: terminal half-life 3.8-6 hours; Ipratropium: terminal half-life 1.5-4 hours (clinical: twice-daily dosing for chronic therapy).
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Albuterol: renal excretion of unchanged drug and metabolites (~60-70% as metabolites, ~10-20% unchanged); Ipratropium: primarily renal (~50% unchanged), with biliary/fecal excretion accounting for minor amounts.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic